Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
45,101,565
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
28,806,277
-
Shares change
-
-84,921
-
Total reported value, excl. options
-
$127,612,664
-
Value change
-
-$6,925,835
-
Put/Call ratio
-
5.5%
-
Number of buys
-
54
-
Number of sells
-
54
-
Price
-
$4.43
Institutional Holders of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) as of Q1 2025
As of 31 Mar 2025 Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) had 130 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 28,806,277 shares of stock of the company.
Largest 10 holders included Paradigm Biocapital Advisors LP, ACORN CAPITAL ADVISORS, LLC, BlackRock, Inc., Caligan Partners LP, Sofinnova Investments, Inc., VANGUARD GROUP INC, Polar Capital Holdings Plc, GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, and BOOTHBAY FUND MANAGEMENT, LLC.
This table shows 130 institutional shareholders of the security as of 31 Mar 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.